Our finding that inhibiting TNFR2 pharmacologically ameliorates lipolysis suggests a new rationale of targeting TNFR2 against cancer morbidity by attenuating cancer associated cachexia through prevention of adipose wasting and muscle atrophy. This evidence concerns the gene TNFRSF1B and cancer.